Hypoglycemic and Hypolipidemic Mechanism of Tea Polysaccharides on Type 2 Diabetic Rats via Gut Microbiota and Metabolism Alteration

2020 ◽  
Author(s):  
Haishan Li ◽  
Qingying Fang ◽  
Qixing Nie ◽  
Jielun Hu ◽  
Chao Yang ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Diabetic Rats ◽  
Tea Polysaccharides ◽  
Type 2 Diabetic

Hypoglycemic and Hypolipidemic Mechanism of Tea Polysaccharides on Type 2 Diabetic Rats via Gut Microbiota and Metabolism Alteration

2020 ◽  
Vol 68 (37) ◽  
pp. 10015-10028
Author(s):  
Haishan Li ◽  
Qingying Fang ◽  
Qixing Nie ◽  
Jielun Hu ◽  
Chao Yang ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Diabetic Rats ◽  
Tea Polysaccharides ◽  
Type 2 Diabetic

scholarly journals Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gut microbiota

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Xiaoyan Wei ◽  
Jinhua Tao ◽  
Suwei Xiao ◽  
Shu Jiang ◽  
Erxin Shang ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Diabetic Rats ◽  
Type 2 Diabetic

scholarly journals The DPP-4 inhibitor sitagliptin alters the gut microbiota and prevents neuronal damage of hippocampus in STZ induced type 2 diabetic rats

2020 ◽  
Author(s):  
Ying Chang ◽  
Ting Xiang ◽  
Hongyan Wang ◽  
Fanlin Zhou ◽  
Jie Liang ◽  
...  
Keyword(s):  
16S Rrna ◽  
Gut Microbiota ◽  
Neuronal Damage ◽  
Diabetic Rats ◽  
16S Rrna Genes ◽  
Rrna Genes ◽  
The Impact ◽  
Central Neuropathy ◽  
Type 2 Diabetic

Abstract Background : Type 2 Diabetes mellitus is characterized by impaired glucose metabolism and insulin resistance with increasing risk of specific complication, including central neuropathy. Dipeptidyl peptidase 4 (DPP-4) inhibitors are agents designed to regulate hyperglicemia through increasing the half-life of incretins. Although they are administered orally, their effects on central neuropathy and gut microbiota remain unclear. Our objective was aimed to identify the impact of the DPP-4 inhibitor sitagliptin on gut microbiota and central neuropathy in a rat model of streptozotocin (STZ)-induced diabetes Methods: Diabetic rats were induced by a high-fat diet and streptozotocin injection. Diabetic rats were orally administered a dose of sitagliptin (10mg/kd/d), and normal diet for 12 weeks. Fecal DNA extraction and sequencing based on analysis of 16S rRNA genes was used to determine the overall structure of microbiota in fecal samples. Then rats were killed, of which the brain tissue sections were observed for changes of neurons in the hippocampus by HE staining. Results: Sequencing of the V3-V4 regions of 16S rRNA genes revealed that sitagliptin significantly altered the gut microbiota. Compared to the diabetic group, Shannon index and the abundance of phylum Bacteroidetes decreased significantly, whereas the proportion of phylum Firmicutes increased significantly in the sitagliptin-treated rats. Moreover, higher abundance of a few putative short-chain fatty acid-producing bacteria, including Clostridium and Fusobacterium was observed remarkably after sitaglitin treatment. Genera Lactobacillus , Streptococcus and Clostridium, which could produce some neurotransmitters, were also found increased substantially in the sitagliptin-treated rats. Notably, we found that sitagliptin treatment could ameliorate the abnormal changes of pyramidal neurons in hippocampus with HE staining. Conclusions: Our study demonstrated that sitagliptin prevented the neuronal damage of hippocampus in type 2 diabetic rats, accompanied by changes of gut microbiome. It indicated that sitagliptin might alleviate diabetic central neuropathy through triggering “microbiota-gut-brain” axis.

scholarly journals Ge-Gen-Jiao-Tai-Wan Affects Type 2 Diabetic Rats by Regulating Gut Microbiota and Primary Bile Acids

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Han Chen ◽  
Ye Yao ◽  
Wenbo Wang ◽  
Dongsheng Wang
Keyword(s):  
Bile Acid ◽  
Gut Microbiota ◽  
Bile Acids ◽  
Intestinal Flora ◽  
Diabetic Rats ◽  
Farnesoid X Receptor ◽  
Rrna Gene ◽  
Fecal Transplant ◽  
Type 2 Diabetic

The Ge-Gen-Jiao-Tai-Wan (GGJTW) formula has been used to treat type 2 diabetes mellitus (T2DM) in China for a long time. Our previous study has proved that GGJTW could alleviate the type 2 diabetic symptoms, but the underlying mechanisms are still unclear. This study aimed to investigate the changes in gut microbiota and primary bile acids (PBAs) to determine the potential mechanisms of GGJTW in treating T2DM.The fecal transplant method and pseudogerm-free rats were used in our study.The16S rRNA gene sequencing method was used to analyze the changes in the intestinal flora, and PBAs in the colon contents were detected. Finally, the expression of farnesoid X receptor (FXR), G protein-coupled membrane receptor 5 (TGR5), and glucagon-like peptide-1 (GLP-1) was assessed. Following GGJTW treatment, we observed a decrease in blood glucose levels and improvements in glucose tolerance and serum lipid levels. Furthermore, we found that GGJTW could regulate the composition of the gut microbiota and upregulate the diabetic beneficial phylum Firmicutes and bile-acid-related genus Lactobacillus. PBAs in the colon contents were increased in the GGJTW-treated group, accompanied by upregulated expression of the bile acid receptors FXR and TGR5 and increased concentrations of GLP-1. These results indicated that GGJTW could alleviate symptoms of type 2 diabetic rats by regulating the gut microbiota, promoting the production of PBAs, and upregulating the PBA-FXR/TGR5-GLP-1 pathway.

Fermented Momordica charantia L. juice modulates hyperglycemia, lipid profile, and gut microbiota in type 2 diabetic rats

2019 ◽  
Vol 121 ◽  
pp. 367-378 ◽  
Author(s):  
He Gao ◽  
Jia-Jia Wen ◽  
Jie-Lun Hu ◽  
Qi-Xing Nie ◽  
Hai-Hong Chen ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Lipid Profile ◽  
Diabetic Rats ◽  
Momordica Charantia ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document